Anti-Cancer

ABIRATERONE ACETATE (BDRON) Tablet

$2,844.00

Abiraterone Acetate BDRON 250/500 Tablet represents a significant therapeutic advance in the management of metastatic castration-resistant prostate cancer, offering targeted therapy that can improve outcomes and quality of life for patients facing this challenging disease. With careful monitoring, patient education, and access to treatment, Abiraterone acetate holds promise in reshaping the landscape of prostate cancer care and providing hope for those affected by this condition.

Strength	Choose an option
	Clear

Quantity

ABIRATERONE ACETATE (BDRON) Tablet quantity

Add to cart

Sku:

N/A

Tag:

ABIRATERONE ACETATE BDRON

Description

Abiraterone Acetate BDRON 250/500 Tablet stands at the forefront of advanced prostate cancer therapy, offering a potent treatment option for patients battling metastatic castration-resistant prostate cancer (mCRPC). With its active ingredient, abiraterone acetate, this tablet represents a significant advancement in the management of this aggressive form of cancer, providing renewed hope and improved outcomes for individuals facing this challenging diagnosis.

Key Features:

• Targeted Therapy: Abiraterone acetate is a potent and selective inhibitor of androgen biosynthesis, specifically targeting the enzyme cytochrome P450 17A1 (CYP17A1) involved in androgen production. By inhibiting androgen synthesis in both the adrenal glands and the tumor microenvironment, it effectively deprives prostate cancer cells of the androgens they require for growth and survival.
• Treatment of mCRPC: Abiraterone acetate BDRON Tablet is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients who have received prior docetaxel chemotherapy, as well as in patients who are chemotherapy-naïve. It offers a valuable therapeutic option for individuals at various stages of the disease, extending survival and improving quality of life.
• Multiple Strengths: Available in tablet form with strengths of 250mg and 500mg, Abiraterone acetate BDRON Tablet allows for personalized dosing tailored to individual patient needs and treatment plans, facilitating optimized therapeutic outcomes.
• Oral Administration: Administered orally once daily, Abiraterone acetate BDRON Tablet is typically taken on an empty stomach, at least one hour before or two hours after a meal. Patients should adhere strictly to the prescribed dosing schedule and follow healthcare provider instructions meticulously.
• Efficacy: Clinical trials have demonstrated the efficacy of abiraterone acetate in prolonging overall survival, delaying disease progression, and improving quality of life in patients with metastatic castration-resistant prostate cancer. It has shown superiority over placebo and other treatments, both in chemotherapy-naïve and post-docetaxel settings.
• Side Effects: Common side effects of Abiraterone acetate may include hypertension, hypokalemia, fluid retention, fatigue, and musculoskeletal pain. Patients should be closely monitored for adverse reactions, and dose adjustments or supportive care measures may be necessary to manage side effects.
• Patient Education: Patients should receive comprehensive counseling on proper medication administration, potential side effects, and the importance of adherence to treatment. They should also be educated on the need for regular monitoring and reporting of any concerning symptoms to their healthcare provider.
• Consultation with Healthcare Provider: Treatment with Abiraterone acetate BDRON Tablet should be initiated and monitored by a qualified oncologist or urologist experienced in the management of prostate cancer. Close collaboration between the patient and healthcare provider is essential throughout the treatment journey.
• Access and Affordability: Efforts should be made to ensure access to Abiraterone acetate for eligible patients, including exploring financial assistance programs and insurance coverage options to mitigate the financial burden of treatment.

In conclusion, Abiraterone Acetate BDRON 250/500 Tablet represents a significant therapeutic advance in the management of metastatic castration-resistant prostate cancer, offering targeted therapy that can improve outcomes and quality of life for patients facing this challenging disease. With careful monitoring, patient education, and access to treatment, Abiraterone acetate holds promise in reshaping the landscape of prostate cancer care and providing hope for those affected by this condition.

Additional information